Analysis of Killer Cell Immunoglobulin-Like Receptor Genes and Their HLA Ligands in Inflammatory Bowel Diseases

Table 4

Activating KIR (aKIR) genotypes in normal individuals and IBD patients.

HLA genotype	HLA gene/allele							Patients (%)	Control (%)	value	OR (95% CI)
	2DS1	2DS2	2DS3	2DS4 F	2DS4 V	2DS5	3DS1
Ulcerative colitis vs. control
1	+	+	+	−	+	+	+	13 (13%)	17 (6.6%)	0.13	1.74 (0.8-3.6)
2	−	+	−	+	+	−	−	3 (3%)	19 (7.4%)	0.16	0.41 (0.1-1.4)
3	−	−	−	+	+	−	−	3 (3%)	15 (5.8%)	0.33	0.53 (0.1-1.9)
4	−	−	−	−	+	−	−	10 (10%)	33 (13.7%)	0.58	0.81 (0.4-1.7)
Crohn’s disease vs. control
1	+	+	−	−	+	+	+	6 (7.2%)	12 (4.6%)	0.30	1.70 (0.6-4.7)
2	+	−	−	−	+	+	+	6 (7.2%)	23 (9.2)	0.73	0.85 (0.3-2.1)
3	+	+	+	−	+	−	−	13 (15.6%)	26 (10.5%)	0.11	1.77 (0.8-3.6)
4	−	−	−	−	+	−	−	4 (4.8%)	33 (13.7%)	0.06	0.37 (0.1-1.1)

A value less than 0.05 was statistically significant. Genotype frequency less than 2% is not included.